Collectively, these results suggest that coinhibition of the MEK pathway and RTK pathways via trametinib plus anlotinib can induce long-term proliferation inhibition in KRAS-mutant NSCLC cells both in vitro and in vivo (Supplementary Fig. 5q). Here, KRAS is linked to non-small cell lung carcinoma.